About Cytoki Pharma

Cytoki Pharma (Cytoki) is a clinical-stage biotechnology company pioneering a new class of medicines that harness the innate biology of IL-22 to address metabolic diseases, including obesity and type 2 diabetes, and conditions characterized by epithelial injury, such as inflammatory bowel disease. Currently in Phase 2 clinical evaluation, CK‑0045, our lead, long-acting IL-22 analogue, is uniquely positioned to meet the medical needs of people living with cardiometabolic diseases by driving lasting disease modification through healthy weight loss and broader, independent metabolic effects. Cytoki was founded in 2019 after licensing of a full IL-22 analogue program from Novo Nordisk.